457 related articles for article (PubMed ID: 28514874)
1. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
[TBL] [Abstract][Full Text] [Related]
2. Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host.
Martinez I; Barrera JC; Rodriguez LL; Wertz GW
Vaccine; 2004 Sep; 22(29-30):4035-43. PubMed ID: 15364454
[TBL] [Abstract][Full Text] [Related]
3. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
4. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
[TBL] [Abstract][Full Text] [Related]
5. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832
[TBL] [Abstract][Full Text] [Related]
6. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
7. Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.
Naik S; Galyon GD; Jenks NJ; Steele MB; Miller AC; Allstadt SD; Suksanpaisan L; Peng KW; Federspiel MJ; Russell SJ; LeBlanc AK
Mol Cancer Ther; 2018 Jan; 17(1):316-326. PubMed ID: 29158470
[TBL] [Abstract][Full Text] [Related]
8. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
11. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
12. Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review.
Moglan AM; Albaradie OA; Alsayegh FF; Alharbi HM; Samman YM; Jalal MM; Saeedi NH; Mahmoud AB; Alkayyal AA
Front Immunol; 2023; 14():1085940. PubMed ID: 37063914
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of pathogenicity of three isolates of vesicular stomatitis virus (Indiana serotype) in pigs.
Morozov I; Davis AS; Ellsworth S; Trujillo JD; McDowell C; Shivanna V; Dasen EJ; Nichols R; Martin BK; Monath TP; Richt JA
J Gen Virol; 2019 Nov; 100(11):1478-1490. PubMed ID: 31553299
[TBL] [Abstract][Full Text] [Related]
14. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
Obuchi M; Fernandez M; Barber GN
J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
[TBL] [Abstract][Full Text] [Related]
15. Effect of strain and serotype of vesicular stomatitis virus on viral shedding, vesicular lesion development, and contact transmission in pigs.
Stallknecht DE; Greer JB; Murphy MD; Mead DG; Howerth EW
Am J Vet Res; 2004 Sep; 65(9):1233-9. PubMed ID: 15478770
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
17. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.
Goel A; Carlson SK; Classic KL; Greiner S; Naik S; Power AT; Bell JC; Russell SJ
Blood; 2007 Oct; 110(7):2342-50. PubMed ID: 17515401
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
Cook J; Peng KW; Witzig TE; Broski SM; Villasboas JC; Paludo J; Patnaik M; Rajkumar V; Dispenzieri A; Leung N; Buadi F; Bennani N; Ansell SM; Zhang L; Packiriswamy N; Balakrishnan B; Brunton B; Giers M; Ginos B; Dueck AC; Geyer S; Gertz MA; Warsame R; Go RS; Hayman SR; Dingli D; Kumar S; Bergsagel L; Munoz JL; Gonsalves W; Kourelis T; Muchtar E; Kapoor P; Kyle RA; Lin Y; Siddiqui M; Fonder A; Hobbs M; Hwa L; Naik S; Russell SJ; Lacy MQ
Blood Adv; 2022 Jun; 6(11):3268-3279. PubMed ID: 35175355
[TBL] [Abstract][Full Text] [Related]
19. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host.
Martinez I; Rodriguez LL; Jimenez C; Pauszek SJ; Wertz GW
J Virol; 2003 Jul; 77(14):8039-47. PubMed ID: 12829843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
